Cybin announces additional adelia milestone achievement

Toronto--(business wire)--cybin inc. (neo:cybn) (nyse american:cybn) (“cybin” or the “company”), a biopharmaceutical company focused on progressing “psychedelics to therapeutics™”, is pleased to announce that adelia therapeutics inc. (“adelia”), a wholly-controlled subsidiary of cybin, has achieved the milestone identified as year 1, q2 (iv) as contemplated by the terms of a contribution agreement dated december 4, 2020 (the “transaction agreement”) among cybin, cybin corp., cybin us holdings i
CYBN Ratings Summary
CYBN Quant Ranking